Investing.com - Financial Markets Worldwide
Cyber Monday Deal: Up to 60% off InvestingProCLAIM SALE

AbbVie's next-generation pan-genotypic HCV regimen shows cure rates as high as 99% after eight weeks

Published 11/11/2016, 10:13 AM
AbbVie's next-generation pan-genotypic HCV regimen shows cure rates as high as 99% after eight weeks
ABBV
-
  • Top-line data from three pivotal studies released by AbbVie (ABBV -1%) today on its pan-genotypic HCV regimen of glecaprevir/pibrentasvir (G/P) showed cure rates of 95 - 99% after eight weeks of therapy. Complete results will be presented at The Liver Meeting in Boston, November 11 - 15.
  • In ENDURANCE-1, the cure rate (SVR12) was 99% (n=348/351) in HCV genotype 1 patients without cirrhosis who were new to treatment or did not respond to previous treatment with peginterferon or sofosbuvir with or without ribavirin. The patient population included patients co-infected with HIV-1.
  • ENDURANCE-3 showed a cure rate of 95% (n=149/157) in treatment-naive HCV genotype 3 patients without cirrhosis.
  • SURVEYOR-2 showed a cure rate of 97% (n=196/203) in HCV genotype 2,4,5 and 6 patients without cirrhosis who were new to treatment or were not cured with previous interferon-based treatments (peginterferon, sofosbuvir with ribavirin, sofosbuvir with peginterferon).
  • The company plans to file its regulatory application in the U.S. this quarter and in Europe and Japan in Q1.
  • G/P is a once-daily fixed-dose combination of 300 mg of glecaprevir, an NS3/4A protease inhibitor and 120 mg of pibrentasvir, an NS5A inhibitor.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.